Vimal Mehta, Ph.D.
CEO & Founder
Dr. Mehta brings over two decades of experience in the pharma and biotech industry, during which he has successfully designed and implemented innovative solutions, established global commercial operations, and led cross-functional teams. During his career, he has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in generating a range of value creation initiatives in corporate strategy and planning, global business development and corporate fundraising.
Frank D. Yocca, Ph.D.
Chief Scientific Officer
Dr. Frank Yocca is an accomplished R&D executive and scientist with extensive experience leading global biopharmaceutical companies. He has wide-ranging expertise in leading high performance, world-class teams in drug discovery and development whose efforts have resulted in a number of prominent neuroscience products including Buspar®, Serzone® Abilify® and Heltioz®. He is a recognized scientific leader in the neuroscience community and member of the Institute of Medicine of the National Academy of Science, and a Fellow of American College of Neuropsychopharmacology. He has 45 referred articles, 96 abstracts and 65 invited presentations.
Vincent J.O'Neill M.D.
Chief Medical Officer
Dr. O'Neill has more than 15 years of therapeutic and diagnostic product development experience, with senior leadership roles at global pharmaceutical companies, including Sanofi, Genentech and GlaxoSmithKline. Most recently, he served as Chief Medical Officer at Mirna Therapeutics and Exosome Diagnostics, where he oversaw global product development and medical affairs. At both Genentech and GlaxoSmithKline, he managed the clinical and biomarker development programs of several oncology therapeutic candidates. He was instrumental in the expanded approval of Genentech's Avastin® and Tarceva® oncology therapeutics. At GSK, he oversaw the signal transduction discovery unit and led the first IND application and clinical trial of MEK inhibitor MEKINIST®.
Luca Rastelli, Ph.D.
VP, Oncology & Translational Science
Dr. Luca Rastelli has more than 20 years of drug discovery and development experience in pharmaceutical, biotech and start-up companies. He has held multiple preclinical and clinical project leadership positions at Curagen, Sopherion, EMD Serono and Boston Strategics. He was also involved in the set up and early development of the approved immuno-oncology agent Bavencio (anti-PDL1). He discovered the target and led the initial development of Glembatumumab vedotin (CR011 anti-GPNMB) through a registrational trial in triple negative metastatic breast cancer. His academic training was focused on how Developmental Biology affects cancerogenesis, and he made important contributions to the role of EZH and REST/NRSF, both involved in the cellular switch that generates neuroendocrine prostate cancer, the target indication for BXCL701. For this work, he received the American Brain Tumor Association's 25th Anniversary Translational grant for his work on Medulloblastoma tumors at the Department of Neuro-Oncology, MD Anderson Cancer Center.
Richard I. Steinhart
VP & CFO
Mr. Steinhart is our Vice President and CFO a role he assumed In October 2017. From October 2015 to June 2017 he was Vice President and CFO at Remedy Pharmaceuticals, Inc., until it sold its only asset, CIRARA, to Biogen for $120M plus earn-outs. From January 2014 through September 2015 Mr. Steinhart worked as a financial and strategic consultant to the biotechnology and medical device industries. From April 2006 through December 2013, Mr. Steinhart was employed by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary. In April 2012, Mr. Steinhart received a promotion to Sr. Vice President, Finance and Chief Financial Officer. From May 1992 until joining MELA Sciences, Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart’s other experience includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer.
Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc., a position he assumed in November 2013 and Atossa Genetics, Inc., where he began his service in March 2014. Mr. Steinhart serves as the Chairman of the Audit Committee at Actinium Pharmaceuticals, where he also sits on the Compensation and Corporate Governance Committees. Mr. Steinhart serves as the Chairman of Atossa Genetics Audit Committee and is a member of its Compensation Committee
Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant (inactive).
VP, Finance & Chief Accounting Officer
Mr. Mahadevan is responsible for leading the finance and accounting functions of the company and has extensive experience and knowledge of finance management in the software and pharmaceutical industries.